Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is a global leader in musculoskeletal healthcare. The company designs, manufactures, and markets orthopedic reconstructive products, including knee and hip replacements, as well as other surgical and dental products. Zimmer Biomet competes with other major players in the medical device industry, such as Stryker Corporation and Johnson & Johnson.
On May 6, 2025, Rick Wise from Stifel Nicolaus set a price target of $115 for Zimmer Biomet. At that time, the stock was trading at $90.48, suggesting a potential upside of approximately 27.1%. However, the stock has faced challenges, including a significant decline of nearly 10% following disappointing first-quarter results.
Despite having structural advantages, Zimmer Biomet is contending with high interest rates, trade tensions, and increased competition. These factors have contributed to the stock’s current price of $90.48, reflecting a decrease of 11.62% with a change of -$11.9. The stock has fluctuated between a low of $89.92 and a high of $99.75 today. The company’s cash flows are expected to be particularly affected by tariffs, which may continue to impact the share price until these issues are addressed. Zimmer Biomet’s market capitalization stands at approximately $17.9 billion, with a trading volume of 6,781,537 shares on the NYSE. Over the past year, the stock reached a high of $122.25 and a low of $89.92.